Page 447«..1020..446447448449..460470..»

Canadian-led team of researchers shows how stem cells can be reprogrammed

By raymumme

TORONTO A Canadian-led international team of researchers has begun solving the mystery of just how a specialized cell taken from a persons skin is reprogrammed into an embryonic-like stem cell, from which virtually any other cell type in the body can be generated.

The research is being touted as a breakthrough in regenerative medicine that will allow scientists to one day harness stem cells to treat or even cure a host of conditions, from blindness and Parkinsons disease to diabetes and spinal cord injuries.

Besides creating the reprogramming roadmap, the scientists also identified a new type of stem cell, called an F-class stem cell due to its fuzzy appearance. Their work is detailed in five papers published Wednesday in the prestigious journals Nature and Nature Communications.

Dr. Andras Nagy, a senior scientist at Mount Sinai Hospital in Toronto, led the team of 50 researchers from Canada, the Netherlands, South Korea and Australia, which spent four years analyzing and cataloguing the day-by-day process that occurs in stem cell reprogramming.

The work builds on the 2006-2007 papers by Shinya Yamanaka, who showed that adult skin cells could be turned into embryonic-like, or pluripotent, stem cells through genetic manipulation, a discovery that garnered the Japanese scientist the Nobel Prize in 2012.

Nagy likened the roughly 21-day process to complete that transformation to a black box, so called because scientists did not know what went on within the cells as they morphed from one cell type into the other.

It was just like a black box, Nagy said Wednesday, following a briefing at the hospital. You start with a skin cell, you arrive at a stem cell but we had no idea what was happening inside the cell.

Nagys team set about cataloguing the changes as they occurred by removing cells from culture dishes at set points during the three-week period, then analyzing such cellular material as DNA and proteins present at that moment.

The result is a database that will be available to scientists around the world, which the team hopes will spur new research to advance the field of stem cell-based regenerative medicine.

Co-author Ian Rogers, a scientist in Nagys lab, said the database will allow researchers to identify various properties of the developing stem cells, which could mean improving their ability to treat or cure disease.

See the original post here:
Canadian-led team of researchers shows how stem cells can be reprogrammed

To Read More: Canadian-led team of researchers shows how stem cells can be reprogrammed
categoriaUncategorized commentoComments Off on Canadian-led team of researchers shows how stem cells can be reprogrammed | dataDecember 11th, 2014
Read All

The NFL Has a Problem with Stem Cell Treatments

By NEVAGiles23

Professional athletes are getting injections of stem cells to speed up recovery from injury. Critics call it a high-tech placebo.

NFL quarterback Peyton Manning reportedly had a stem cell treatment to his neck in 2011.

Elite athletes do whatever it takes to win. Lately, thats meant getting an injection of their own stem cells.

The treatments, developed over the last eight years, typically involve extracting a small amount of a players fat or bone marrow and then injecting it into an injured joint or a strained tendon to encourage tissue regeneration. Bone marrow contains stem cells capable of generating new blood cells, cartilage, and bone.

Although the treatments have become a multimillion-dollar industry, some doctors say theres only thin medical evidence they actually speed healing. In a report issued last week, public policy researchers at Rice University criticized the National Football Leagues role in promoting unproven treatments to the public. Some players, including Peyton Manning of the Denver Broncos and Sidney Rice, whos now retired but won a Super Bowl with the Seattle Seahawks last year, have reportedly gone overseas for stem cell treatments and others have acted as spokespeople for U.S. clinics offering them.

The Rice researchers, Kirstin Matthews and Maude Cuchiara, say the NFL should create an independent panel and fund research on whether stem cell treatments actually work, similar to what it did after facing questions around concussions and brain injury. I think they should be more proactive. They should get ahead of this one, says Matthews.

Sports Illustrated reports that hundreds of football players have gotten stem cell treatments, with many travelling abroad for types of therapy not offered in the United States.But its not only football players trying them. The tennis player Rafael Nadal is reportedly undergoing stem cell treatments for back pain, and the injections are also being sought out by soccer players and high school athletes.

The NFL didnt respond to questions from MIT Technology Review. Doctors offering the treatments say theyre promising and should be given a chance. Others say theres not enough data. Any of these injections have a placebo effect, says Freddie Fu, an orthopedic surgeon who is chairman of sports medicine at the University of Pittsburgh Medical Center and top doctor for the schools sports teams. We dont know what we are putting in. We dont really know what exactly what it does, biologically.

Orthopedic surgeons hope one day to use stem cells to regenerate cartilage and other lost tissue. But wishful thinking, and profits, have gotten ahead of the facts, says Fu. Theres a lot of marketing in orthopedics right now. I would say 15 to 20 percent of treatments are not effective, he says.

Unlike a drug, which gets tested for years and is then weighed by experts and the U.S. Food and Drug Administration before hitting the market, the bone marrow treatments offered in the U.S. arent regulated.

See the rest here:
The NFL Has a Problem with Stem Cell Treatments

To Read More: The NFL Has a Problem with Stem Cell Treatments
categoriaUncategorized commentoComments Off on The NFL Has a Problem with Stem Cell Treatments | dataDecember 11th, 2014
Read All

Researchers show how stem cells can be reprogrammed

By raymumme

TORONTO A Canadian-led international team of researchers has begun solving the mystery of just how a specialized cell taken from a persons skin is reprogrammed into an embryonic-like stem cell, from which virtually any other cell type in the body can be generated.

The research is being touted as a breakthrough in regenerative medicine that will allow scientists to one day harness stem cells to treat or even cure a host of conditions, from blindness and Parkinsons disease to diabetes and spinal cord injuries.

Besides creating the reprogramming roadmap, the scientists also identified a new type of stem cell, called an F-class stem cell due to its fuzzy appearance. Their work is detailed in five papers published Wednesday in the prestigious journals Nature and Nature Communications.

Dr. Andras Nagy, a senior scientist at Mount Sinai Hospital in Toronto, led the team of 50 researchers from Canada, the Netherlands, South Korea and Australia, which spent four years analyzing and cataloguing the day-by-day process that occurs in stem cell reprogramming.

The work builds on the 2006-2007 papers by Shinya Yamanaka, who showed that adult skin cells could be turned into embryonic-like, or pluripotent, stem cells through genetic manipulation, a discovery that garnered the Japanese scientist the Nobel Prize in 2012.

Nagy likened the roughly 21-day process to complete that transformation to a black box, so called because scientists did not know what went on within the cells as they morphed from one cell type into the other.

It was just like a black box, Nagy said Wednesday, following a briefing at the hospital. You start with a skin cell, you arrive at a stem cell but we had no idea what was happening inside the cell.

Nagys team set about cataloguing the changes as they occurred by removing cells from culture dishes at set points during the three-week period, then analyzing such cellular material as DNA and proteins present at that moment.

The result is a database that will be available to scientists around the world, which the team hopes will spur new research to advance the field of stem cell-based regenerative medicine.

Co-author Ian Rogers, a scientist in Nagys lab, said the database will allow researchers to identify various properties of the developing stem cells, which could mean improving their ability to treat or cure disease.

Go here to read the rest:
Researchers show how stem cells can be reprogrammed

To Read More: Researchers show how stem cells can be reprogrammed
categoriaUncategorized commentoComments Off on Researchers show how stem cells can be reprogrammed | dataDecember 11th, 2014
Read All

The Latest in Stem Cell Therapy – Video

By Dr. Matthew Watson


The Latest in Stem Cell Therapy
Dr. MIchael Belich of integrative Medical Clinics talks about the latest therapies using Stem Cells.

By: Integrative Medical Clinics

Read more:
The Latest in Stem Cell Therapy - Video

To Read More: The Latest in Stem Cell Therapy – Video
categoriaUncategorized commentoComments Off on The Latest in Stem Cell Therapy – Video | dataDecember 11th, 2014
Read All

R3 Stem Cell Welcomes Beverly Hills Pain Specialists Dr. George Graf as a Featured Regenerative Medicine Doctor

By Sykes24Tracey

Beverly Hills, CA (PRWEB) December 11, 2014

R3 Stem Cell is proud to welcome Dr. George Graf as a Featured Regenerative Medicine Doctor in the Los Angeles and Beverly Hills area. Dr. Graf is a first rate pain management doctor, who offers several types of stem cell procedures and platelet rich plasma therapy for all types of spinal conditions such as neck and back pain, arthritis, disc degeneration and more. Those interested should call (844) GET-STEM for more information and scheduling.

R3 Stem Cell is a nationwide provider of regenerative medicine products and education for both doctors and patients. The company only works with the top doctors and practices in the field of stem cell therapy. Dr. Graf is Double Board Certified and is very highly regarded by his peers and patients.

The conditions Dr. Graf treats include degenerative disc disease, spinal arthritis, scoliosis, neuropathy, failed back surgery syndrome and more. Regenerative medicine offers the potential to not only bring pain relief, but also help repair and regenerate damaged tissue.

Along with Dr. Graf being a regenerative medicine expert in the LA and Beverly Hills area, R3 also works with Dr. Raj. Dr. Raj is a Double Board Certified orthopedic specialist, who offers regenerative medicine procedures for rotator cuffs, hip and knee arthritis, sports injuries and much more. Between Dr. Graf and Dr. Raj, the whole body is covered for treatments.

All of the treatment options are outpatient and very low risk. Platelet Rich Plasma Therapy involves a person's own blood, which is immediately processed and injected into the problem area. Bone marrow derived stem cell therapy involves an aspiration from one's iliac crest, with the material being processed to concentrate stem cells and then inject into the problem area. Additionally, amniotic stem cells are offered, with the fluid being obtained from a consenting donor undergoing a scheduled C-section. The fluid is processed at an FDA regulated lab and no fetal tissue is involved whatsoever.

To date, several small studies have shown excellent benefit with regenerative medicine procedures. This has been extremely encouraging, and allowed stem cell therapy to exponentially increase in popularity nationwide. R3 Stem Cell is at the forefront in regenerative medicine, teaming with the top doctors such as Drs. Raj and Graf to help patients achieve pain relief and avoid surgery.

Call (844) GET-STEM today for more information and scheduling with a top stem cell doctor today.

Read the original:
R3 Stem Cell Welcomes Beverly Hills Pain Specialists Dr. George Graf as a Featured Regenerative Medicine Doctor

To Read More: R3 Stem Cell Welcomes Beverly Hills Pain Specialists Dr. George Graf as a Featured Regenerative Medicine Doctor
categoriaUncategorized commentoComments Off on R3 Stem Cell Welcomes Beverly Hills Pain Specialists Dr. George Graf as a Featured Regenerative Medicine Doctor | dataDecember 11th, 2014
Read All

Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Innovative Targeted Payload …

By JoanneRUSSELL25

Contact Information

Available for logged-in reporters only

Newswise An innovative targeted payload immunotherapy that is being readied for a Phase 3 clinical trial (due to begin in the first half of 2015), received a favorable endorsement from Actinium Pharmaceuticals Scientific Advisory Board (SAB). The nod occurred after the members conducted its year-end meeting to review the progress of Iomab-B, a radiolabeled antibody being developed as a part of bone marrow transplant regimen initially in relapsed and refractory AML patients ages 55 and older.

The group met prior to the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco and was Chaired by John Pagel, MD PhD of the Fred Hutchinson Cancer Research Center and Swedish Cancer Institute in Seattle and included senior members from Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and other leading institutions. The SABs goal is to further the development of Iomab-B as a myeloablative agent for older relapsed and refractory AML patients. If approved, Iomab-B should increase the number of patients eligible for curative bone marrow transplant (BMT, also known as HSCT) and improve clinical outcomes.

Richard Champlin MD, Chair of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center, stated, We are impressed with progress in Iomab-B development and are looking forward to starting the trial. Iomab-B treatment would be an important new addition to our unfortunately very limited armamentarium for the most difficult-to-treat AML patients, and could potentially change the way refractory AML in older patients is treated.

As an international leader in the field of hematopoietic stem cell transplantation (HSCT), Dr. Champlin pioneered the use of donor transplants and lower doses of chemotherapy, reducing mortality rates along the way. Under his leadership, the MD Anderson HSCT program grew to become the largest in the world.

The Company updated the SAB on progress made in 2014, including refining and completing the Phase 3 protocol, progress in manufacturing centralization and scale-up, CRO engagement and the completion of other administrative items. Plans for 2015 were also reviewed, including assembly of the IND (Investigational New Drug) Application for submission to FDA early next year, clinical trial sites selection, preparation of ancillary materials and other items related to the upcoming pivotal trial. This study is planned as the final clinical trial prior to potential FDA clearance and approval.

Dr. Dragan Cicic, Chief Medical Officer of Actinium stated: "Actinium is committed to the ongoing development of Iomab-B with a multi-center Phase 3 pivotal trial due to begin in 2015. With the continued support and input from our world renowned scientific advisors, we are moving quickly to advance Iomab-B development. The SAB meeting further supported our belief that, if approved by FDA, Iomab-B could significantly change the treatment paradigm for elderly relapsed and refractory AML patients by providing a potentially curative pathway for majority of patients who today have a life expectancy of 5 or fewer months."

About AML Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow. It is characterized by an uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates there will be approximately 18,860 new cases of AML and approximately 10,460 deaths from AML in the U.S. in 2014, most of them in adults. Patients over age 60 comprise the majority of those diagnosed with AML, with a median age of a patient diagnosed with AML being 67 years. Treatment approaches in this population are limited because a majority of these individuals are judged too frail and unable to tolerate standard induction chemotherapy or having forms of disease generally unresponsive to currently available drugs. Elderly, high risk patients ordinarily have a life expectancy of 5 or fewer months if treated with standard chemotherapy, and only about a third of them receive this treatment because of toxicity of and limited responses to the available therapy. The other two-thirds receive best supportive care, with 2 months survival, according to Oran and Weisdorf (Haematologica 2012; 1916-24).

About Iomab-B Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

See original here:
Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Innovative Targeted Payload ...

To Read More: Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Innovative Targeted Payload …
categoriaBone Marrow Stem Cells commentoComments Off on Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Innovative Targeted Payload … | dataDecember 10th, 2014
Read All

Tommy’s Experience with Stem Cell Therapy – Video

By daniellenierenberg


Tommy #39;s Experience with Stem Cell Therapy
Tommy discusses living with debilitating back pain and choosing stem cell therapy followed by hyperbaric oxygen therapy to improve his quality of life. Learn more at http://beyondpills.com/,...

By: PainSpecialistCenter

Go here to read the rest:
Tommy's Experience with Stem Cell Therapy - Video

To Read More: Tommy’s Experience with Stem Cell Therapy – Video
categoriaUncategorized commentoComments Off on Tommy’s Experience with Stem Cell Therapy – Video | dataDecember 10th, 2014
Read All

Some NFL Players Use Unproven Stem Cell Therapies: Report

By LizaAVILA

Latest Exercise & Fitness News

MONDAY, Dec. 8, 2014 (HealthDay News) -- Some professional football players are seeking unproven stem cell therapies to speed their recovery from injuries. But experts are concerned that they may be unaware of the potential risks, a new report shows.

Stem cell therapy has attracted the attention of elite athletes. A number of National Football League (NFL) players have highlighted their use of those therapies and their successful recoveries.

Twelve NFL players are known to have received unapproved stem cell treatments since 2009.

"The online data on NFL players and the clinics where they obtained treatment suggest that players may be unaware of the risks they are taking," report co-author Kirstin Matthews, a fellow in science and technology policy at Rice University's Baker Institute for Public Policy, said in a university news release.

"Players who are official spokespersons for these clinics could influence others to view the therapies as safe and effective despite the lack of scientific research to support these claims," she added.

Most of the players receive treatment in the United States, but several have gone to other countries for stem cell therapies that aren't available in the United States.

"With the rise of new and unproven stem cell treatments, the NFL faces a daunting task of trying to better understand and regulate the use of these therapies in order to protect the health of its players," Matthews said.

The NFL and other sports leagues may need to evaluate and possibly regulate stem cell therapies in order to ensure the safety of their players, the report authors suggested.

The paper appears in a special supplement to the journal Stem Cells and Development.

See original here:
Some NFL Players Use Unproven Stem Cell Therapies: Report

To Read More: Some NFL Players Use Unproven Stem Cell Therapies: Report
categoriaUncategorized commentoComments Off on Some NFL Players Use Unproven Stem Cell Therapies: Report | dataDecember 10th, 2014
Read All

Billionaire Paul Allen Pledges Millions for Cell Science

By raymumme

Software billionaire Paul Allen says he's committing $100 million to create a new institute in Seattle focusing on the mechanics of human cell biology.

The Allen Institute for Cell Science's first project, the Allen Cell Observatory, will focus on creating computational models for the kinds of induced pluripotent stem cells, or IPS cells, that have the ability to turn into heart muscle cells or the epithelial cells that form the inner linings of organs as well as skin.

Such cells hold promise for facilitating research into how cells become diseased, and potentially for growing replacement tissues.

"Cells are the fundamental units of life, with every disease we know of affecting particular types of cells," Allen said in a news release. "Scientists have learned a great deal about many of the 50 trillion cells in our bodies over the last decades, but creating a comprehensive, predictive model of the cell will require a different approach."

The Allen Cell Observatory's goal is to produce a dynamic, visual database and animated models of cell parts in action. Such models could shed light on the processes by which genetic information is translated into cellular functions, and reveal what goes wrong in a diseased cell. That, in turn, could help researchers predict which therapies will work best to counter diseases, or perhaps head off the disease in the first place.

Allen's latest philanthropic venture was unveiled Monday at the American Society for Cell Biology's annual meeting in Philadelphia. It follows up on plans that the co-founder of Microsoft has had in mind for years.

"It's the right time to start a big initiative in cell biology: understanding how cells work, understanding the detailed things that happen inside cells, which is behind cancer and Alzheimer's and all those things," Allen told NBC News last year.

Software billionaire Paul Allen's latest philanthropic project is a $100 million commitment to create the Allen Institute for Cell Science.

Paul Allen's net worth is estimated at more than $17 billion. Over the past 15 years, he has contributed hundreds of millions of dollars to scientific projects including the Allen Telescope Array, the Allen Institute for Brain Science and the Allen Institute for Artificial Intelligence. Last month, he said he would contribute $100 million to the global fight against the Ebola virus. (Allen also owns somewhat less-scientific ventures, such as the Seattle Seahawks and the Portland Trail Blazers.)

The cell science institute will be housed in the seven-story Allen Institute headquarters building that is currently under construction in Seattle's South Lake Union neighborhood. The building is scheduled for completion in the fall of 2015, and will also house the Allen Brain Institute.

View post:
Billionaire Paul Allen Pledges Millions for Cell Science

To Read More: Billionaire Paul Allen Pledges Millions for Cell Science
categoriaSkin Stem Cells commentoComments Off on Billionaire Paul Allen Pledges Millions for Cell Science | dataDecember 9th, 2014
Read All

Microsoft Co-Founder Establishes Cell Institute with $100 Million Grant

By JoanneRUSSELL25

Seattle After tackling the brain, the Ebola epidemic, and a host of other issues, billionaire Paul Allen has a new target for scientific philanthropy: unraveling the inner workings of human cells.

On Monday, the Microsoft co-founder announced a $100 million, five-year grant to establish the Allen Institute for Cell Science in Seattle.

The goal is to better understand the teeming world inside cells, where thousands of organelles and millions of molecules interact in a dynamic ballet that researchers are just beginning to fathom.

We really dont have a good idea of how normal cells work, and what goes wrong in disease, said Rick Horwitz, the former University of Virginia professor who jumped at the chance to lead the new institute. People spend careers trying to understand little parts of the cell, but nobody has stitched it together because its too complicated for any individual to study.

The institute will take on the challenge by combining new technologies, like microscopes that can visualize living cells in three dimensions, with enough computational firepower to make sense of the flood of data that will result, Horwitz said.

Eventually, he and his team hope to develop computer models that mimic living cells. If they succeed, those models could also shed light on what goes haywire in cancer and other diseases and help develop cures, he said.

At a time when federal research budgets are shrinking, the announcement is one of the most exciting things to happen in Seattle science in a long time, said Dr. Chuck Murry, co-director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington. When the Allen folks get into something, they do it at a scale thats just mind-blowing.

The grant is one of Allens largest, on par with the $100 million he committed earlier this year to fight Ebola in West Africa, and a $100 million grant in 2003 to establish the Seattle-based Allen Institute for Brain Science. He has since plowed an additional $300 million into the brain institute.

Allen, who joined his old partner Bill Gates in pledging to donate the bulk of his wealth, has stepped up his philanthropic efforts in recent years. Its a good bet he will continue investing in the cell institute as long as it measures up, said Allan Jones, who leads the Allen Institute for Brain Science and helped organize its new sister institute.

We need to knuckle down and show that we can deliver something very powerful, Jones said.

View post:
Microsoft Co-Founder Establishes Cell Institute with $100 Million Grant

To Read More: Microsoft Co-Founder Establishes Cell Institute with $100 Million Grant
categoriaUncategorized commentoComments Off on Microsoft Co-Founder Establishes Cell Institute with $100 Million Grant | dataDecember 9th, 2014
Read All

Future of Care: The Future of Stem Cell Therapy Highlights – Video

By Dr. Matthew Watson


Future of Care: The Future of Stem Cell Therapy Highlights
A few highlights from our October 29, 2014 Future of Care: Future of Stem Cell Therapy event featuring UC San Diego Health System CEO Paul Viviano, Director of Sanford Stem Cell Clinical Center...

By: UCSDHSDEV

Read this article:
Future of Care: The Future of Stem Cell Therapy Highlights - Video

To Read More: Future of Care: The Future of Stem Cell Therapy Highlights – Video
categoriaUncategorized commentoComments Off on Future of Care: The Future of Stem Cell Therapy Highlights – Video | dataDecember 9th, 2014
Read All

Ageless Derma Launches Its Latest Moisturizing Product Featuring Exotic Apple Stem Cells

By JoanneRUSSELL25

Irvine, California (PRWEB) December 08, 2014

The Ageless Derma skin care company has added a moisturizing product to their line that provides continuous hydration to skin throughout the day. The Swiss Apple Stem Cell Oil-Free Continuous Moisturizer uses rare Swiss apple stem cells in combination with other natural substances to aid in skins retention of moisture for a lessening of fine lines and a silky, more comfortable feeling.

The Swiss Apple Stem Cell Oil-Free Continuous Moisturizer contains stem cells from the exotic Malus Domestica, a rare apple from Switzerland known for its long shelf life and its ability to stay fresh without shriveling. This apple species had a flavor that consumers found too acidic, making farmers reluctant to grow it. The Malus Domestica, however, was discovered to have interesting scientific advantages due to its ability to live a long, healthy life without the usual shriveling that accompanies fruit as it ages. The same idea has been transferred to Ageless Dermas latest moisturizer with its incorporation of these stem cell extracts for a renewed and rejuvenated facial complexion. The stem cells help with not only apple longevity, but also with repairing human skin cells. This results in the ultimate reduction of fine lines and wrinkles with regular use.

Other ingredients are added to the Swiss Apple Stem Cell Oil-Free Continuous Moisturizer to make this moisturizer a workhorse of anti-aging and hydrating skin renewal. Ceramides and essential fatty acids account for maximum skin hydration and strengthening of the skin barrier function. Capric Triglycerides silken skin, glycerin keeps moisturization and hydration in balance, and Ceramides 3, 611, and 1 (all lipids) stop moisture from escaping and hold the skin barrier intact. Swiss Apple Stem Cell Oil-Free Continuous Moisturizer also has sodium hyaluronate to attract and keep moisture in. The hyaluronate also aids in blood microcirculation and the smoothing of wrinkles.

The developers at Ageless Derma Skin Care know they are making something extraordinary happen. Their line of physician-grade skin care products incorporates an important philosophy: supporting overall skin health by delivering the most cutting-edge biotechnology and pure, natural ingredients to all of the skin's layers. This attitude continues to resonate to this day with the companys founder, Dr. Farid Mostamand, who nearly ten years ago began his journey to deliver the best skin care alternatives for people who want to have healthy and beautiful looking skin at any age. About this latest Ageless Derma product, Dr. Mostamand says, The Swiss Apple Stem Cell Oil-Free Continuous Moisturizer is a multi-beneficial product that protects skin and works to smooth lines and wrinkles as it keeps moisture in, working throughout the entire day. Without the correct distribution of moisture, skin becomes dry and susceptible to wrinkling. This product is oil-free and can be used for any skin type.

Ageless Derma products are formulated in FDA-approved Labs. All ingredients are inspired by nature and enhanced by science. Ageless Derma products do not contain parabens or any other harsh additives, and they are never tested on animals. The company has developed five unique lines of products to address any skin type or condition.

View original post here:
Ageless Derma Launches Its Latest Moisturizing Product Featuring Exotic Apple Stem Cells

To Read More: Ageless Derma Launches Its Latest Moisturizing Product Featuring Exotic Apple Stem Cells
categoriaSkin Stem Cells commentoComments Off on Ageless Derma Launches Its Latest Moisturizing Product Featuring Exotic Apple Stem Cells | dataDecember 8th, 2014
Read All

Asymmetrex – Video

By Sykes24Tracey


Asymmetrex
Technologies For Stem Cell Medicine.

By: Asymmetrex

The rest is here:
Asymmetrex - Video

To Read More: Asymmetrex – Video
categoriaUncategorized commentoComments Off on Asymmetrex – Video | dataDecember 8th, 2014
Read All

Improved case of Anky Spondy after PRP and Stem Cell Therapy – Video

By daniellenierenberg


Improved case of Anky Spondy after PRP and Stem Cell Therapy
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

The rest is here:
Improved case of Anky Spondy after PRP and Stem Cell Therapy - Video

To Read More: Improved case of Anky Spondy after PRP and Stem Cell Therapy – Video
categoriaUncategorized commentoComments Off on Improved case of Anky Spondy after PRP and Stem Cell Therapy – Video | dataDecember 8th, 2014
Read All

Future of Care: The Future of Stem Cell Therapy (Full Presentation) – Video

By raymumme


Future of Care: The Future of Stem Cell Therapy (Full Presentation)
Watch our October 29, 2014 Future of Care presentation on the future of stem cell therapy featuring Dr. David Brenner, Vice Chancellor, UC San Diego Health Sciences, Paul Viviano, Chief Executive...

By: UCSDHSDEV

Continue reading here:
Future of Care: The Future of Stem Cell Therapy (Full Presentation) - Video

To Read More: Future of Care: The Future of Stem Cell Therapy (Full Presentation) – Video
categoriaUncategorized commentoComments Off on Future of Care: The Future of Stem Cell Therapy (Full Presentation) – Video | dataDecember 7th, 2014
Read All

Loss of a chemical tag on RNA keeps embryonic stem cells in suspended animation

By JoanneRUSSELL25

A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.

The team also included scientists from Harvard Medical School, Massachusetts General Hospital and Stanford University.

Published in the journal Cell Stem Cell, the research reveals that depleting or knocking out a key component of the machinery that places this chemical tag -- known both as m6A and N6-methyladenosine -- on RNA significantly blocks embryonic stem cells from differentiating into more specialized types of cells.

A key property of embryonic stem cells is their ability to differentiate into many specialized types of cells. However, instead of marching toward a specific fate when prompted by signals to differentiate, embryonic stem cells that have reduced ability to place m6A become stuck in a sort of suspended animation, even though they appear healthy.

Yi Xing, a UCLA associate professor of microbiology, immunology and molecular genetics, led the informatics analyses and was a co-corresponding author of the paper. Other corresponding authors were Dr. Cosmas Giallourakis, an assistant professor of medicine at Harvard Medical School and Massachusetts General Hospital, and Dr. Howard Chang, a professor of Stanford University's School of Medicine and a Howard Hughes Medical Institute investigator.

The study of naturally occurring chemical modifications on RNAs is part of an emerging field known as epitranscriptomics. The m6A tag is the most commonly occurring modification known to scientists; it is found on RNAs of thousands of protein-coding genes and hundreds of non-coding genes in a typical cell type. The tags may help regulate RNA metabolism by marking them for destruction.

Little was known about the dynamics, conservation and function of m6A in human or mouse embryonic stem cells when the authors began the project. The authors analyzed which RNAs were tagged with m6A and the location of the m6A modifications along RNAs in mouse and human embryonic stem cells.

"Our analysis revealed a high level of conservation of m6A patterns between mice and humans, suggesting that m6A has conserved functions in human and mouse embryonic stem cells," Xing said. "Moreover, RNAs with m6A tags were degraded more rapidly and lived a shorter life in the cell than those without."

The investigators then found a strikingly conserved requirement for the presence of normal levels of m6A for differentiating embryonic stem cells into multiple cell types. Depletion of METTL3, a gene encoding the enzyme that places the m6A tag on RNAs, severely blocked human embryonic stem cells from differentiating into the gut or neural precursors. Deletion of the mouse METTL3 gene also led to a severe block in the ability of embryonic stem cells to differentiate into neural and cardiac lineages.

The study suggests that m6A modifications on RNA make the transition between cell states possible by instructing the cells to physically degrade those RNAs marked by m6A in embryonic stem cells, to allow the cells to become another cell type. However, if the cells can no longer tag RNA for destruction, the cells lose the ability to change. This discovery sheds new light on gene regulation in stem cells.

Here is the original post:
Loss of a chemical tag on RNA keeps embryonic stem cells in suspended animation

To Read More: Loss of a chemical tag on RNA keeps embryonic stem cells in suspended animation
categoriaCardiac Stem Cells commentoComments Off on Loss of a chemical tag on RNA keeps embryonic stem cells in suspended animation | dataDecember 6th, 2014
Read All

Vast Majority of Life-Saving Cord Blood Sits Unused

By raymumme

High costs keep patients from using stem cells harvested from umbilical cords

Scientists are studying ways to treat HIV, cerebral palsy and other diseases using umbilical cord blood, although little of the collected blood will actually be used. Credit:Banc de Sang via flickr

Youd think doctors and patients would be clamoring for cells so versatile they could help reboot a body suffering from everything from leukemia to diabetes. But a new report shows that an important source of these stem cellsdiscarded umbilical cordsis rarely used because of high costs and the risk of failure.

Stem cells drawn from newborns umbilical cord blood are sometimes used to treat medical conditions, especially bone and blood cancers like multiple myeloma or lymphoma by replacing dysfunctional blood-producing cells in bone marrow. Generally the diseased cells are destroyed with chemotherapy and irradiation. Then new stem cells are transplanted into the patient to restore function. Cord blood stem cells are an alternative to bone marrow transplants and peripheral blood transplants, in which stem cells are gathered from the blood stream. Cord blood tends to integrate better with the body and it is easier to find a suitable donor than the alternatives.

Yet less than 3 percent of cord blood collected in the U.S. is ever used whereas the rest sits uselessly in blood banks, according to a recent report in Genetic Engineering & Biotechnology News. Immunologist Enal Razvi is author of the report and managing director of Select Biosciences, a biotechnology consulting agency. Razvi found that public cord blood banks, which store donated frozen units for transplants as needed, have only a 1 to 3 percent turnover annually. Most of their inventory sits unused year after year. For example, at Community Blood Services in New Jersey, patients have only used 278 of its 13,000 cords since it opened in 1996, according to business development director Misty Marchioni. Usage is even lower at private cord blood banks, which charge clients thousands of dollars to store a cord in the event a family member one day needs it.

Unlike bone marrow, the main alternative stem cell source, cells transplanted from cord blood carry little risk of graft-versus-host disease, a deadly condition in which the body rejects a transplant. Scientists believe this is because a babys immune system is closer to a blank slate, so their stem cells can integrate with the patients body more easily. But cord blood transplants also take longer to start working, requiring longer hospital stays and upping the bill. Due to storage and testing costs, the cords themselves also get pricy. The cost of the cord is prohibitively high, Razvi explains. Each unit of cord blood costs between $35,000 and $40,000 and most adults require two units for a successful transplant. Insurance companies will generally pay a set amount for a stem cell transplant regardless of where the cells come from. The price tag on a cord blood transplant can run up to $300,000, which may not be fully covered.

Cord blood stem cell transplants also have a higher failure rate than other transplant methods. If the transplant fails, it leaves patients with a compromised immune system in addition to their original disease and medical bills. Because the preparation for transplant includes wiping out the patients original bone marrow, the entire body has to be repopulated with stem cells able to replace it. There are not many stem cells in each cord. Compared with bone marrow or peripheral blood there is a greater chance that there will not be enough stem cells that actually implant and begin producing blood and bone marrow. Its like spreading a small amount of seeds in a big garden, says Mitchell Horwitz, who teaches cell therapy at Duke University Medical Center. Sometimes it just doesnt take.

Martin Smithmyer, chief executive of the private bank Americord, claims that more clients will eventually use their cords, especially as more applications are found for cord blood stem cells. But some scientists disagree. Steven Joffe, a professor of medical ethics at the University of Pennsylvania Perelman School of Medicine, says that many treatments cannot be done with a patients own stem cells because genetic diseases would already be present in the cord blood and that bone marrow might be a better option for relatives. The likelihood they are ever going to use that product is vanishingly small, he says.

Despite the low usage, advocates say cord blood programs have been crucial in improving transplant options for racial minorities, because it can be hard to find a bone marrow match for some groups. Cord blood does not need to match the patient as perfectly as bone marrow. This has transformed the treatment of minority patients, says Andromachi Scaradavou, medical director of the National Cord Blood Program, a public bank based in New York City. In the past we didnt have good donors to offer them. Community Blood Servicess Marchioni also maintains that cord blood is a good emergency option, because finding a compatible bone marrow or peripheral blood donor can take months or years. If you need a transplant quickly, she says, its easy to get cord blood off of a shelf.

Still, experts are working on more efficient ways of ensuring widespread availability of cord blood without having so much of it sit forever unused. Researchers are also continuing to look for ways to improve transplant success and to increase the number of stem cells obtained from each cord, potentially bringing down costs and making cord blood transplants feasible for more patients. If the cost could be lowered, Scaradavou says, it would help a lot of patients get the treatment they need.

More here:
Vast Majority of Life-Saving Cord Blood Sits Unused

To Read More: Vast Majority of Life-Saving Cord Blood Sits Unused
categoriaBone Marrow Stem Cells commentoComments Off on Vast Majority of Life-Saving Cord Blood Sits Unused | dataDecember 6th, 2014
Read All

Use of Unproven Stem Cell Therapy Questioned

By Sykes24Tracey

Robert Vondracek has had multiple sclerosis for 20 years. His speech is starting to slur and he's been having more trouble getting around, and when he heard about a controversial stem cell therapy that might help, he got excited.

"I heard about the stem cell treatments being done right here in Phoenix," said Vondracek, 61. "It shocked me because it was not approved in this country, I didn't think."

The therapy was offered by an Arizona plastic surgeon who gives the stem cell treatments in the same clinic where he does cosmetic procedures.

But when Vondracek's neurologist heard about his interest in the therapy, which would cost $7,000 per treatment, "He went crazy," said Vondracek. He strongly advised Vondracek against it.

Plastic surgeons, other doctors and naturopaths at more than 100 clinics round the country are charging thousands of dollars for a controversial procedure called stem cell therapy to treat a range of disorders, including neurological diseases like MS and Parkinson's.

Robert Vondracek and his girlfriend, Terese Knapik.

The procedure has angered many neurologists and prominent researchers who say these doctors are preying on vulnerable people and capitalizing on the huge but still unrealized potential of stem cell research, which they say is years away from producing an approved treatment for neurological diseases.

"Peddling snake oil in the guise of stem cell therapies is really a threat to legitimate research," said Dr. George Daley, director of the Stem Cell Transplantation Program at Boston Children's Hospital, past president of the International Society for Stem Cell Research and a professor at Harvard Medical School.

"Finding cures is hard, it takes sometimes decades, it's extremely expensive and it's not something that we can just wish and hope for," he said. "It can only be achieved through very, very hard work."

Dr. George Daley is a nationally recognized expert on stem cells at Boston Childrens Hospital and Harvard Medical School.

Read more here:
Use of Unproven Stem Cell Therapy Questioned

To Read More: Use of Unproven Stem Cell Therapy Questioned
categoriaUncategorized commentoComments Off on Use of Unproven Stem Cell Therapy Questioned | dataDecember 6th, 2014
Read All

New single-cell analysis reveals complex variations in stem cells

By Dr. Matthew Watson

Stem cells offer great potential in biomedical engineering due to their pluripotency, which is the ability to multiply indefinitely and also to differentiate and develop into any kind of the hundreds of different cells and bodily tissues. But the precise complexity of how stem cell development is regulated throughout states of cellular change has been difficult to pinpoint until now.

By using powerful new single-cell genetic profiling techniques, scientists at the Wyss Institute for Biologically Inspired Engineering and Boston Children's Hospital have uncovered far more variation in pluripotent stem cells than was previously appreciated. The findings, reported today in Nature, bring researchers closer to a day when many different kinds of stem cells could be leveraged for disease therapy and regenerative treatments.

"Stem cell colonies contain much variability between individual cells. This has been considered somewhat problematic for developing predictive approaches in stem cell engineering," said the study's co-senior author James Collins, Ph.D., who is a Wyss Institute Core Faculty member, the Henri Termeer Professor of Medical Engineering & Science at MIT, and a Professor of Biological Engineering at MIT. "Now, we have discovered that what was previously considered problematic variability could actually be beneficial to our ability to precisely control stem cells."

The research team has learned that there are many small fluctuations in the state of a stem cell's pluripotency that can influence which developmental path it will follow.

It's a very fundamental study but it highlights the wide range of states of pluripotency," said George Daley, study co-senior author, Director of Stem Cell Transplantation at Boston Children's Hospital and a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. "We've captured a detailed molecular profile of the different states of stem cells."

Taking this into account, researchers are now better equipped to manipulate and precisely control which cell and tissue types will develop from an individual pluripotent stem cell or stem cell colony.

"The study was made possible through the use of novel technologies for studying individual cells, which were developed in part by collaborating groups at the Broad Institute, giving our team an unprecedented view of stem cell heterogeneity at the individual cell level," said Patrick Cahan, co-lead author on the study and Postdoctoral Fellow at Boston Children's Hospital and Harvard Medical School.

Researchers explored the developmental landscape of pluripotent stem cells by perturbing them with variants such as different chemicals, culture environments, and genetic knockouts. Then, they analyzed the individual genetic makeup of each cell to observe micro-fluctuations in each stem cell's state of pluripotency. They discovered many small nuances in the way stem cells are influenced by internal, chemical and environmental cues, revealing a complex "decision making" circuit of developmental regulators.

"These emerging single-cell analytics allow us to classify cells very precisely and identify regulatory circuits that control cell states," said the study's co-lead author Roshan Kumar, a former Wyss Institute Postdoctoral Fellow who is now a Senior Scientist at HiFiBiO Inc. and a Visiting Scholar at the Wyss Institute. "The real motivating force behind this study was to understand the causes and consequences of differences between individual stem cells and how the balance of key regulators within a cell can affect that cell's developmental outcome."

Looking at the findings, the researchers now believe there is a "code" that relates patterns of dynamic behavior in stem cell regulatory circuits to the developmental path a cell ends up taking. By leveraging that code, they hope to dial in precisely to specific individual cell states and to use them for a variety of purposes, such as creating certain cell types that a patient's body may be unable to produce on its own.

View post:
New single-cell analysis reveals complex variations in stem cells

To Read More: New single-cell analysis reveals complex variations in stem cells
categoriaUncategorized commentoComments Off on New single-cell analysis reveals complex variations in stem cells | dataDecember 6th, 2014
Read All

Cord blood educator meets neuroscientist

By Dr. Matthew Watson

Marion Welch and Dr. Paul Sanberg

Ridgefielder and cord blood advocate Marion Welch recently met Dr. Paul Sanberg, aneuroscientist and cord blood stem cell researcher and currently distinguished professor at the College of Medicine and Molecular Pharmacology and Physiology at the University of Southern Florida.

Ms. Welch has been educating parents in Connecticut and New York for the past 15 years on preserving cord blood stem cells at the time of birth. She serves as a senior member of Cryo-Cell Internationals field cord blood educator team.

Dr. Sanberg is the author of more than 600 scientific articles and has published 13 books, including Neural Stem Cells: Methods and Protocols and Neural Stem Cells for Brain and Spinal Cord Repair, and is an inventor with more than 100 United States patents. His work is pioneering the clinical use of using cord blood stem cells to treat neurological disorders, Ms. Welch said.

Connecticut has mandated cord blood education for all expectant parents for the last five years.

For more information on cord blood banking, contact Marion Welch at mwelch@cryo-cell.com

For more information on Dr. Sanberg and his research, contact USF Research & Innovation, 3702 Spectrum Blvd., Suite 165, Tampa FL 33612.

Original post:
Cord blood educator meets neuroscientist

To Read More: Cord blood educator meets neuroscientist
categoriaSpinal Cord Stem Cells commentoComments Off on Cord blood educator meets neuroscientist | dataDecember 5th, 2014
Read All

Page 447«..1020..446447448449..460470..»


Copyright :: 2024